Relay Therapeutics Inc
NASDAQ:RLAY

Watchlist Manager
Relay Therapeutics Inc Logo
Relay Therapeutics Inc
NASDAQ:RLAY
Watchlist
Price: 4.24 USD 1.92%
Market Cap: 709.7m USD
Have any thoughts about
Relay Therapeutics Inc?
Write Note

Intrinsic Value

RLAY's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one RLAY stock under the Base Case scenario is 1.89 USD. Compared to the current market price of 4.24 USD, Relay Therapeutics Inc is Overvalued by 55%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

RLAY Intrinsic Value
1.89 USD
Overvaluation 55%
Intrinsic Value
Price
Base Case Scenario

Valuation History
Relay Therapeutics Inc

Intrinsic Value History
Dive into the past to invest in the future

Uncover deeper insights with the Valuation History. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start now and learn if your stock is truly undervalued or overvalued!

Start Valuation
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Valuation History Unavailable

Historical valuation for RLAY cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
How do you feel about RLAY?
Bearish
Neutral
Bullish

Fundamental Analysis

4.24 USD
+1.92%
+1.92%
Benchmark
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Relay Therapeutics Inc
US
Biotechnology
Market Cap
707.6m USD
IPO
Jul 16, 2020
Employees
245
United States of America
Market Cap
707.6m USD
Industry
Biotechnology
IPO
Jul 16, 2020
Company Overview
Loading...
Economic Moat
Loading...
Management
Loading...
Contacts
Loading...
AI Assistant
AI Assistant
Ask me anything about Relay Therapeutics Inc

Provide an overview of the primary business activities
of Relay Therapeutics Inc.

What unique competitive advantages
does Relay Therapeutics Inc hold over its rivals?

What risks and challenges
does Relay Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Relay Therapeutics Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Relay Therapeutics Inc.

Provide P/S
for Relay Therapeutics Inc.

Provide P/E
for Relay Therapeutics Inc.

Provide P/OCF
for Relay Therapeutics Inc.

Provide P/FCFE
for Relay Therapeutics Inc.

Provide P/B
for Relay Therapeutics Inc.

Provide EV/S
for Relay Therapeutics Inc.

Provide EV/GP
for Relay Therapeutics Inc.

Provide EV/EBITDA
for Relay Therapeutics Inc.

Provide EV/EBIT
for Relay Therapeutics Inc.

Provide EV/OCF
for Relay Therapeutics Inc.

Provide EV/FCFF
for Relay Therapeutics Inc.

Provide EV/IC
for Relay Therapeutics Inc.

Show me price targets
for Relay Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Relay Therapeutics Inc?

How accurate were the past Revenue estimates
for Relay Therapeutics Inc?

What are the Net Income projections
for Relay Therapeutics Inc?

How accurate were the past Net Income estimates
for Relay Therapeutics Inc?

What are the EPS projections
for Relay Therapeutics Inc?

How accurate were the past EPS estimates
for Relay Therapeutics Inc?

What are the EBIT projections
for Relay Therapeutics Inc?

How accurate were the past EBIT estimates
for Relay Therapeutics Inc?

Compare the revenue forecasts
for Relay Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Relay Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Relay Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Relay Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Relay Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Relay Therapeutics Inc with its peers.

Analyze the financial leverage
of Relay Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Relay Therapeutics Inc.

Provide ROE
for Relay Therapeutics Inc.

Provide ROA
for Relay Therapeutics Inc.

Provide ROIC
for Relay Therapeutics Inc.

Provide ROCE
for Relay Therapeutics Inc.

Provide Gross Margin
for Relay Therapeutics Inc.

Provide Operating Margin
for Relay Therapeutics Inc.

Provide Net Margin
for Relay Therapeutics Inc.

Provide FCF Margin
for Relay Therapeutics Inc.

Show all solvency ratios
for Relay Therapeutics Inc.

Provide D/E Ratio
for Relay Therapeutics Inc.

Provide D/A Ratio
for Relay Therapeutics Inc.

Provide Interest Coverage Ratio
for Relay Therapeutics Inc.

Provide Altman Z-Score Ratio
for Relay Therapeutics Inc.

Provide Quick Ratio
for Relay Therapeutics Inc.

Provide Current Ratio
for Relay Therapeutics Inc.

Provide Cash Ratio
for Relay Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Relay Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Relay Therapeutics Inc?

What is the current Free Cash Flow
of Relay Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Relay Therapeutics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Relay Therapeutics Inc

Current Assets 865.1m
Cash & Short-Term Investments 839.6m
Other Current Assets 25.5m
Non-Current Assets 65m
PP&E 60.6m
Intangibles 2.3m
Other Non-Current Assets 2.1m
Current Liabilities 47m
Accounts Payable 6.9m
Accrued Liabilities 38.7m
Other Current Liabilities 1.4m
Non-Current Liabilities 44.3m
Other Non-Current Liabilities 44.3m
Efficiency

Earnings Waterfall
Relay Therapeutics Inc

Revenue
35.6m USD
Operating Expenses
-696m USD
Operating Income
-660.5m USD
Other Expenses
56.8m USD
Net Income
-603.7m USD

Free Cash Flow Analysis
Relay Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

RLAY Profitability Score
Profitability Due Diligence

Relay Therapeutics Inc's profitability score is 13/100. The higher the profitability score, the more profitable the company is.

Exceptional 1-Year Revenue Growth
Declining ROE
Negative Revenue Growth Forecast
Declining ROIC
13/100
Profitability
Score

Relay Therapeutics Inc's profitability score is 13/100. The higher the profitability score, the more profitable the company is.

RLAY Solvency Score
Solvency Due Diligence

Relay Therapeutics Inc's solvency score is 72/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
Average Altman Z-Score
72/100
Solvency
Score

Relay Therapeutics Inc's solvency score is 72/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

RLAY Price Targets Summary
Relay Therapeutics Inc

Wall Street analysts forecast RLAY stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RLAY is 22.44 USD with a low forecast of 16.16 USD and a high forecast of 31.5 USD.

Lowest
Price Target
16.16 USD
281% Upside
Average
Price Target
22.44 USD
429% Upside
Highest
Price Target
31.5 USD
643% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for RLAY?

Click here to dive deeper.

Dividends

Relay Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for RLAY is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

RLAY Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

RLAY News

Other Videos

See Also

Discover More
What is the Intrinsic Value of one RLAY stock?

The intrinsic value of one RLAY stock under the Base Case scenario is 1.89 USD.

Is RLAY stock undervalued or overvalued?

Compared to the current market price of 4.24 USD, Relay Therapeutics Inc is Overvalued by 55%.

Back to Top